Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care

Journal of General Internal Medicine

Volumn 27, Issue 6, 2012, Pages 669-676

  Schackman, Bruce R ^a   Leff, Jared A ^a   Polsky, Daniel ^b   Moore, Brent A ^c   Fiellin, David A ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

buprenorphine naloxone; cost effectiveness; opioid substitution therapy; primary health care

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; OPIATE ADDICTION; PRIMARY MEDICAL CARE; QUALITY OF LIFE;

BUPRENORPHINE; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; LONG-TERM CARE; MEDICATION ADHERENCE; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 84862679923     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1962-8     Document Type: Article

References (49)

1. Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results. htm. Accessed November 10, 2011.
2. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction 1998 Effective medical treatment of opiate addiction JAMA 280 22 1936 1943 10.1001/jama.280.22.1936
3. DA Fiellin GH Friedland MN Gourevitch 2006 Opioid dependence: rationale for and efficacy of existing and new treatments Clin Infect Dis 43 Suppl 4 S173 177 17109303 10.1086/508180 1:CAS:528:DC%2BD2sXitVamtg%3D%3D
4. RE Johnson T Eissenberg ML Stitzer EC Strain IA Liebson GE Bigelow 1995 A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence Drug Alcohol Depend 40 1 17 25 8746920 10.1016/0376-8716(95)01186-2 1:CAS:528:DyaK28XitVKisLo%3D
5. J Kakko KD Svanborg MJ Kreek M Heilig 2003 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial Lancet 361 9358 662 668 12606177 10.1016/S0140-6736(03)12600-1 1:CAS:528:DC%2BD3sXhsVajt7k%3D
6. W Ling C Charuvastra JF Collins, et al. 1998 Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial Addiction 93 4 475 486 9684386 10.1046/j.1360-0443.1998.9344753.x 1:STN:280:DyaK1czkvFSisw%3D%3D
7. RP Mattick R Ali JM White S O'Brien S Wolk C Danz 2003 Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients Addiction 98 4 441 452 12653814 10.1046/j.1360-0443. 2003.00335.x
8. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003(2):CD002207.
9. CSAT Buprenorphine Information Center. Drug Addiction Treatment Act of 2000. http://buprenorphine.samhsa.gov/data.html. Accessed November 10, 2011.
10. CL Arfken CE Johanson S di Menza CR Schuster 2010 Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians J Subst Abuse Treat 39 2 96 104 20598829 10.1016/j.jsat.2010.05.004
11. Clark HW. The State of Buprenorphine Treatment. Paper presented at: Buprenorphine in the Treatment of Opioid Addiction: Reassessment 2010; May 10, 2010; Washington, DC.
12. Evaluation of the Buprenorphine Waiver Program: Buprenorphine Reimbursement and Availability Tracking Study. http://www.avisagroup.com/images/ Final-Report-of-Tracking-Study.pdf. Accessed November 10, 2011.
13. BR Schackman JO Merrill D McCarty J Levi C Lubinski 2006 Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care Clin Infect Dis 43 Suppl 4 S247 253 17109311
14. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ ob/default.cfm. Accessed November 10, 2011.
15. Murray L, ed. Red book 2010 pharmacy's fundamental reference. Montvale, NJ: Thomson PDR; 2010.
16. DA Fiellin 2007 The first three years of buprenorphine in the United States: experience to date and future directions J Addict Med 1 2 62 21768936 10.1097/ADM.0b013e3180473c11
17. RE Clark M Samnaliev JD Baxter GY Leung 2011 The Evidence Doesn't Justify Steps By State Medicaid Programs To Restrict Opioid Addiction Treatment With Buprenorphine Health Aff (Millwood) 30 8 1425 1433 10.1377/hlthaff.2010.0532
18. Anonymous. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
19. JM Pyne S Tripathi M French K McCollister RC Rapp BM Booth 2011 Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes Addiction 106 3 507 515 21205046 10.1111/j.1360-0443.2010.03299.x
20. B Nosyk H Sun DP Guh, et al. 2010 The quality of eight health status measures were compared for chronic opioid dependence J Clin Epidemiol 63 10 1132 1144 20236799 10.1016/j.jclinepi.2009.12.003
21. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
22. RS Braithwaite DO Meltzer JT King Jr D Leslie MS Roberts 2008 What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46 4 349 356 18362813 10.1097/MLR. 0b013e31815c31a7
23. PA Ubel RA Hirth ME Chernew AM Fendrick 2003 What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 163 14 1637 1641 12885677 10.1001/archinte.163.14.1637
24. Tan-Torres Edejer T, Baltussen R, Adam T, et al., eds. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization; 2003.
25. DA Fiellin BA Moore LE Sullivan, et al. 2008 Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years Am J Addict 17 2 116 120 18393054 10.1080/10550490701860971
26. DA Fiellin MV Pantalon MC Chawarski, et al. 2006 Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence N Engl J Med 355 4 365 374 16870915 10.1056/NEJMoa055255 1:CAS:528:DC%2BD28Xnt12qtro%3D
27. DP Alford CT Labelle N Kretsch, et al. 2011 Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience Arch Intern Med 171 5 425 431 21403039 10.1001/archinternmed.2010.541
28. JM Soeffing LD Martin MI Fingerhood DR Jasinski DA Rastegar 2009 Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year J Subst Abuse Treat 37 4 426 430 19553061 10.1016/j.jsat.2009.05.003
29. M Gossop J Marsden D Stewart T Kidd 2003 The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results Addiction 98 3 291 303 12603229 10.1046/j.1360-0443.2003.00296.x
30. BA Moore DA Fiellin DT Barry, et al. 2007 Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients J Gen Intern Med 22 4 527 530 17372805 10.1007/s11606-007-0129-0
31. ES Jones BA Moore JL Sindelar PG O'Connor RS Schottenfeld DA Fiellin 2009 Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients Drug Alcohol Depend 99 1-3 132 140 18804923 10.1016/j.drugalcdep.2008.07.013
32. U.S. Department of Labor Bureau of Labor Statistics. National Compensation Survey. http://data.bls.gov. Accessed November 10, 2011.
33. State of Connecticut Department of Labor, History of minimum wage laws. http://www.ctdol.state.ct.us/wgwkstnd/wage-hour/history.htm. Accessed November 10, 2011.
34. M Connock A Juarez-Garcia S Jowett, et al. 2007 Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation Health Technol Assess 11 9 1 171 17313907 1:STN:280:DC%2BD2s7hvVKguw%3D%3D iii-iv
35. K Stein M Dyer T Crabb, et al. 2006 A pilot Internet "value of health" panel: recruitment, participation and compliance Health Qual Life Outcomes 4 90 17129380 10.1186/1477-7525-4-90
36. RG Frank DS Salkever 1997 Generic entry and the pricing of pharmaceuticals J Econ Manage Strategy 6 1 75 90 10.1162/105864097567039
37. JP Santell 1996 Projecting future drug expenditures-1996 Am J Health Syst Pharm 53 2 139 150 8653479 1:STN:280:DyaK283mtlCisQ%3D%3D
38. D Polsky HA Glick J Yang GA Subramaniam SA Poole GE Woody 2010 Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial Addiction 105 9 1616 1624 20626379 10.1111/j.1360-0443.2010.03001.x
39. GE Woody SA Poole G Subramaniam, et al. 2008 Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial JAMA 300 17 2003 2011 18984887 10.1001/jama.2008.574
40. The EuroQol Group 1990 EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 3 199 208 10.1016/0168-8510(90) 90421-9
41. R Brooks 1996 EuroQol: the current state of play Health Policy 37 1 53 72 10158943 10.1016/0168-8510(96)00822-6 1:STN:280:DyaK283otFKhsg%3D%3D
42. JW Shaw JA Johnson SJ Coons 2005 US valuation of the EQ-5D health states: development and testing of the D1 valuation model Med Care 43 3 203 220 15725977 10.1097/00005650-200503000-00003
43. Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom: Oxford University Press; 2006.
44. The Mental Health Parity and Addiction Equity Act. http://cciio.cms.gov/ programs/protections/mhpaea/mhpaea-factsheet.html. Accessed November 10, 2011.
45. SD Grosse 2008 Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold Expert Rev Pharmacoecon Outcomes Res 8 2 165 178 20528406 10.1586/14737167.8.2.165
46. PG Barnett GS Zaric ML Brandeau 2001 The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States Addiction 96 9 1267 1278 11672491 10.1046/j.1360-0443.2001.96912676.x 1:STN:280:DC%2BD3MrmsFKjtg%3D%3D
47. MD Stein P Cioe PD Friedmann 2005 Buprenorphine retention in primary care J Gen Intern Med 20 11 1038 1041 16307630 10.1111/j.1525-1497.2005.0228.x
48. TV Parran CA Adelman B Merkin, et al. 2010 Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy Drug Alcohol Depend 106 1 56 60 19717249 10.1016/j.drugalcdep.2009.07.013 1:CAS:528:DC%2BD1MXhsFygu7%2FO
49. U.S. Department of Health & Human Services. Centers for Medicare & Medicaid Services. http://www.cms.hhs.gov/. Accessed November 10, 2011.